G

Monte Rosa Therapeutics
D

GLUE

12.140
USD
-0.46
(-3.65%)
Post Trading·12.280USD+0.140(+1.15%)
Volume
28,708
EPS
-1
Div Yield
-
P/E
-7
Market Cap
1,035,704,688
Overview
Related Instruments
BKNG
BKNG
D
Booking Holdings
167.790
-2.830(-1.66%)
167.900+0.110(+0.07%)
DHR
DHR
D
Danaher Corp
211.790
-0.690(-0.32%)
EXPE
EXPE
D
Expedia Group
279.38
-5.16(-1.81%)
H
H
D
Hyatt Hotels Corp
155.190
0.511(0.33%)
HLT
HLT
D
Hilton Worldwide Holdings
305.74
3.21(1.06%)
HON
HON
D
Honeywell International
206.360
-0.110(-0.05%)
206.300-0.060(-0.03%)
IHG
IHG
D
InterContinental Hotels Group Plc
153.160
-0.040(-0.03%)
MAR
MAR
D
Marriott International
339.07
5.23(1.57%)
M
MIDD
D
Middleby Corp
112.320
0.950(0.85%)
OKE
OKE
D
Oneok
93.440
0.230(0.25%)
94.950+1.510(+1.62%)
PNW
PNW
D
Pinnacle West Capital Corp
94.230
-1.340(-1.40%)
T
TRIP
D
TripAdvisor
8.82000
-0.07000(-0.79%)
T
TRVG
D
trivago NV
6.59000
-0.07000(-1.05%)
More
Articles
GLUE article featured image

What Is the DAX and How to Invest in It?

Learn what the DAX index is, how it works, which companies it includes, and how you can invest or trade it. A practical guide for retail investors and traders.

3 weeks ago
Trading Beginners
More

Title: Monte Rosa Therapeutics

Sector: Healthcare
Industry: Biotechnology
Monte Rosa Therapeutics Inc is a clinical-stage biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. The company has three programsin clinical development: MRT-6160, a VAV1-directed MGD for immune-mediated diseases; MRT-8102, a NEK7-directed MGD for inflammatory diseases driven by IL-6, and the NLRP3 inflammasome; and MRT-2359, a GSPT1-directed MGD for metastatic castration resistant prostate cancer (mCRPC).
Smarter Decisions,Together
FacebookTwitterYoutubeLinkedIn
App Store
iOS
Google Play
Android

Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Never invest money you cannot afford to lose, and carefully assess the suitability of complex products such as CFDs and derivatives in light of your financial situation. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes.

Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

© 2026 - Arincen L.L.C-FZ - License No. 2420098.01. All Rights Reserved.